The present invention relates to a method of treating a cachexia and/or sarcopenia with an oral dose of S-pindolol or a pharmaceutical formulation thereof and to an oral formulation for use in said method of treatment. The method and oral formulation comprise administering a total daily dose of 2.5 to 20mg of S-pindolol or a pharmaceutical formulation comprising the same.

Composicion farmacéutica de administracion oral que contiene ésteres alquílicos de ácidos grasos poliinsaturados (PUFA) y principios activos farmacéuticos betabloqueantes para el tratamiento y/o prevencion de enfermedades cardiovasculares. Reivindicacion 2: Composicion farmacéutica segun la reivindicacion 1 donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos pertenecen a la serie omega-3. Reivindicacion 4: Composicion farmacéutica segun la reivindicacion 1 donde el radical alqui...

La presente invencion se refiere al uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomas por ejemplo de un los hemangiomas infantiles. El beta bloqueante puede ser un beta bloqueante no selectivo por ejemplo propranolol. La presente invencion proporciona una alternativa a los compuestos conocidos por ej. corticoides interferon o vincristina que se usan generalmente para el tratamiento de los hemangiomas. Reivindicacion 4: El uso de acuerdo con la...

Reivindicacion 1 Un dispositivo de ruptura de liberacion controlada caracterizado porque comprende a) un nucleo que comprende al menos un agente activo y al menos un excipiente; b) una membrana semipermeable que encierra al nucleo y que comprende al menos un pasaje preformado que la atraviesa y una region debilitada; y c) una subcapa que controla la ruptura entre el nucleo y la membrana semipermeable donde la membrana semipermeable se rompe en una region debilitada durante el uso debido al incre...

In accordance with the present invention it has been discovered that pindolol provides a highly effective treatment for PMS and/or PMDD. As such the present invention generally relates to methods and compositions for treating and/or preventing PMS or symptoms associated therewith including premenstrual tension or premenstrual dysphoria. The methods and compositions of the invention also involves the use of pindolol a known beta adrenergic blocker in combination with known contraceptives.

The present invention provides a method for treating fibromyalgia and/or chronic fatigue syndrome by administering an antagonist or partial agonist of 5HT1a receptors.

The present invention relates to compositions and methods of treating human subjects with a beta-adrenergic receptor blocking agent (“beta-blocker”) provided in a time-sustained-release delivery system. The time-sustained-release drug delivery systems includes at least three populations of beads where each population of beads includes a beta-blocker. The beads may be selected from immediate-release beads enteric-release beads sustained-release beads and time-sustained-release beads. The beta-blo...